{"id":"W4286293830","doi":"10.1200/jco.2022.40.16_suppl.tps1118","title":"KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Medicine; Metastatic breast cancer; Pembrolizumab; Internal medicine; Oncology; Breast cancer; Chemotherapy; Cancer; Placebo; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002138143,0.002248089,0.002819666,0.0005893714,0.0006465292,0.001372045,0.001447862,0.002596339,0.01497299],"category_scores_gemma":[0.001548692,0.000954794,0.001589672,0.0005456624,0.001159234,0.001529482,0.0004873352,0.004419992,0.002509474],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000912755,"about_ca_system_score_gemma":0.002015651,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001034463,"about_ca_topic_score_gemma":0.002866541,"domain_scores_codex":[0.9994518,0.0002414093,0.00003294346,0.0001155993,0.0000471572,0.000111047],"domain_scores_gemma":[0.9992586,0.0001530557,0.0001638358,0.00005656379,0.0000589671,0.0003090513],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9525773,0.02222148,0.0003787029,0.001031549,0.000677812,0.00004967359,0.00005569692,0.0002701717,0.005609087,0.0001588811,0.001822357,0.01514725],"study_design_scores_gemma":[0.9589924,0.03930616,0.000617219,0.00002121827,0.0001438146,0.0000193676,0.000009709393,0.0001483392,0.0001858424,0.00006086339,0.0004866273,0.000008349944],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9436646,0.009736627,0.002154945,0.001831094,0.001814232,0.02766915,0.005757425,0.0006648524,0.006707204],"genre_scores_gemma":[0.9451028,0.006131553,0.00448665,0.004690602,0.0009234902,0.02722035,0.003886688,0.00009086813,0.007466897],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01497299,"threshold_uncertainty_score":0.0500896,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07995130304151785,"score_gpt":0.4552754857975471,"score_spread":0.3753241827560293,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}